Identify the critical protein‐coding genes and long noncoding RNAs in cardiac myxoma

Abstract

Cardiac myxoma (CM) is the most common benign cardiac tumor which is mostly sporadic. Increasing evidence show that protein-coding genes (PCGs) and long noncoding RNAs (lncRNAs) play important roles in the pathology processes of multiple cancers. However, the functional roles and regulatory mechanisms of RNAs interaction in CM are still unclear. In this study, we investigated three pairs of surgically excised CM by high throughput sequencing and screened a set of PCGs and lncRNAs which were differentially expressed and could serve as expression markers in CM. By constructing protein-protein interactions (PPI) and lncRNA-mRNA coexpressing network, we screened out a CM-related hub lncRNA-mRNA modules, which were enriched in different pathways such as MAPK and TGF-beta whose imbalance were validated by q-PCR. In addition, we identified a specific dysregulated competing endogenous RNA (ceRNA) network in CM by integrating lncRNA-miRNA-mRNA interactions. These results will help us to understand the interaction mechanisms of RNAs in CM and provide novel PCGs and lncRNAs as potential therapeutic targets for CM. K E Y W O R D S cardiac myxoma, ceRNA, lncRNA, mRNA J Cell Biochem. 2019;120:13441-13452.wileyonlinelibrary.com/journal/jcb

miRNAs in Cardiac Myxoma: New Pathologic Findings for Potential Therapeutic Opportunities

“…The importance of miRNAs in cardiac development and heart function in cases of ischemic disease has been shown in recent years [ 1 , 3 , 5 , 6 , 7 , 8 , 9 , 10 , 11 ]. Early stages of cardiac development are controlled by miR-1 and miR-133a, resulting in commitment of cardiac-specific muscle lineage from embryonic stem cells and mesodermal precursors [ 12 ].…”

“…Cardiac automaticity is regulated by miR-1/133a, while miR-208/499 regulates expression of contractile proteins. In cardiac pathology, expression of cardiac miRNAs is markedly altered [ 1 , 3 , 5 , 6 , 7 , 8 , 9 , 10 , 11 ], leading to acute (ischemia-reperfusion and apoptosis) and chronic (fibrosis, hypertrophy, and remodeling) adverse effects. In acute myocardial infarction, circulating levels of cardiac miRNAs are significantly elevated, making them a promising marker for early diagnosis [ 5 ].…”

Visual analysis based on CiteSpace software: a bibliometric study of atrial myxoma

“…The current surgical methods used to treat atrial myxoma fall into the following four categories: (1) resection of atrial myxoma by median thoracotomy (12); (2) small incision resection of atrial myxoma (13); (3) thoracoscopic-assisted resection of atrial myxoma (14); and (4) complete endoscopic resection of atrial myxoma (including total thoracoscopic cardiac surgery and robotic cardiac surgery) (15,16). With rapid developments in the understanding of myxoma at the genetic and molecular level, new targeted drugs may be developed (17,18); however, some controversy remains. Therefore, it is meaningful to gain knowledge on the development of cardiac myxoma.…”